X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NOVARTIS AJANTA PHARMA/
NOVARTIS
 
P/E (TTM) x 20.4 328.0 6.2% View Chart
P/BV x 4.8 36.4 13.2% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 AJANTA PHARMA   NOVARTIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
NOVARTIS
Mar-18
AJANTA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,818758 239.8%   
Low Rs1,106579 191.0%   
Sales per share (Unadj.) Rs239.5228.4 104.9%  
Earnings per share (Unadj.) Rs52.831.7 166.3%  
Cash flow per share (Unadj.) Rs59.532.8 181.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs230.0297.1 77.4%  
Shares outstanding (eoy) m88.7724.69 359.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.12.9 208.6%   
Avg P/E ratio x27.721.1 131.5%  
P/CF ratio (eoy) x24.620.4 120.4%  
Price / Book Value ratio x6.42.2 282.6%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m129,78216,505 786.3%   
No. of employees `0006.80.7 1,017.2%   
Total wages/salary Rs m3,7651,445 260.5%   
Avg. sales/employee Rs Th3,128.48,441.3 37.1%   
Avg. wages/employee Rs Th554.02,163.6 25.6%   
Avg. net profit/employee Rs Th689.71,173.1 58.8%   
INCOME DATA
Net Sales Rs m21,2585,639 377.0%  
Other income Rs m2421,718 14.1%   
Total revenues Rs m21,4997,357 292.2%   
Gross profit Rs m6,584-63 -10,534.2%  
Depreciation Rs m59625 2,355.3%   
Interest Rs m455 7.4%   
Profit before tax Rs m6,2261,575 395.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,539792 194.4%   
Profit after tax Rs m4,686784 598.1%  
Gross profit margin %31.0-1.1 -2,794.3%  
Effective tax rate %24.750.3 49.2%   
Net profit margin %22.013.9 158.6%  
BALANCE SHEET DATA
Current assets Rs m12,2369,522 128.5%   
Current liabilities Rs m3,4613,296 105.0%   
Net working cap to sales %41.3110.4 37.4%  
Current ratio x3.52.9 122.4%  
Inventory Days Days6037 164.4%  
Debtors Days Days8428 297.2%  
Net fixed assets Rs m11,14046 24,217.2%   
Share capital Rs m177123 143.4%   
"Free" reserves Rs m20,2377,213 280.6%   
Net worth Rs m20,4147,336 278.3%   
Long term debt Rs m100-   
Total assets Rs m24,48611,105 220.5%  
Interest coverage x1,519.429.5 5,153.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 171.0%   
Return on assets %19.27.6 253.6%  
Return on equity %23.010.7 214.9%  
Return on capital %30.522.2 137.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66761 19,253.0%   
Fx outflow Rs m1,6163,630 44.5%   
Net fx Rs m10,052-3,570 -281.6%   
CASH FLOW
From Operations Rs m2,8541,610 177.3%  
From Investments Rs m-2,604687 -379.1%  
From Financial Activity Rs m-2-2,677 0.1%  
Net Cashflow Rs m248-380 -65.4%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 2.0 77.5%  
FIIs % 7.6 1.6 475.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.5 79.1%  
Shareholders   20,968 41,647 50.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS